151 related articles for article (PubMed ID: 9865258)
1. Hypertriglyceridemia in renal transplant recipients treated with sirolimus.
Brattström C; Wilczek HE; Tydén G; Böttiger Y; Säwe J; Groth CG
Transplant Proc; 1998 Dec; 30(8):3950-1. PubMed ID: 9865258
[No Abstract] [Full Text] [Related]
2. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients.
Maramattom BV; Wijdicks EF
Neurology; 2004 Nov; 63(10):1958-9. PubMed ID: 15557524
[TBL] [Abstract][Full Text] [Related]
3. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz WA
Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
[No Abstract] [Full Text] [Related]
4. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.
Smak Gregoor PJ; Hesse CJ; van Gelder T; van der Mast BJ; IJzermans JN; van Besouw NM; Weimar W
Transplant Proc; 1998 Jun; 30(4):1192-3. PubMed ID: 9636482
[No Abstract] [Full Text] [Related]
5. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
Chueh SC; Kahan BD
Transplantation; 2003 Jul; 76(2):375-82. PubMed ID: 12883196
[TBL] [Abstract][Full Text] [Related]
6. Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft.
Mizuno Y; Kikuchi H; Fujimori K; Doi H; Orii T; Ohkohchi N; Satomi S
Transplant Proc; 2000 Nov; 32(7):1677-8. PubMed ID: 11119888
[No Abstract] [Full Text] [Related]
7. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients.
Fritsche L; Sperschneider H; Budde K; Giessing M; Morgera S; Schröder K; Stein G; Neumayer HH
Transplant Proc; 1998 Jun; 30(4):1190-1. PubMed ID: 9636481
[No Abstract] [Full Text] [Related]
8. Clinical study of FK 506 in renal transplant recipients.
Youhua Z; Zhinlian M; Liming W
Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900
[No Abstract] [Full Text] [Related]
9. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy.
Chen J; Li L; Wen J; Tang Z; Ji S; Sha G; Cheng Z; Sun Q; Cheng D; Liu Z
Transplant Proc; 2008 Jun; 40(5):1411-5. PubMed ID: 18589119
[TBL] [Abstract][Full Text] [Related]
10. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study.
Charpentier B; Groth CG; Bäckman L; Morales JM; Calne R; Kreis H; Lang P; Touraine JL; Claesson K; Campistol JM; Durand D; Wramner L; Brattström C;
Transplant Proc; 2003 May; 35(3 Suppl):58S-61S. PubMed ID: 12742468
[TBL] [Abstract][Full Text] [Related]
11. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
13. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
Friemann S; Feuring E; Padberg W; Ernst W
Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
[No Abstract] [Full Text] [Related]
14. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization.
Nakache R; Weinbroum A; Merhav H; Katz P; Kaplan E
Transplant Proc; 2001 May; 33(3):2294-5. PubMed ID: 11377533
[No Abstract] [Full Text] [Related]
15. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A.
Massy ZA; De Bandt JP; Morelon E; Thevenin M; Lacour B; Kreis H
Nephrol Dial Transplant; 2000 Jun; 15(6):928. PubMed ID: 10831671
[No Abstract] [Full Text] [Related]
16. Conversion to sirolimus in a population of kidney and kidney-pancreas transplant recipients.
Almeida M; Martins LS; Dias L; Figueiredo MJ; Henriques AC; Sarmento AM; Cabrita A
Transplant Proc; 2005; 37(6):2777-80. PubMed ID: 16182808
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
[No Abstract] [Full Text] [Related]
18. Steroid withdrawal in renal transplant recipients.
Oppenheimer F
Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
[No Abstract] [Full Text] [Related]
19. Lipid profile in renal transplant recipients under various immunosuppressive regimens.
Montagnino G; Tarantino A; Aroldi A; Banfi G; Cesana B; Ponticelli C
Transplant Proc; 1994 Oct; 26(5):2634-6. PubMed ID: 7940821
[No Abstract] [Full Text] [Related]
20. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations.
Tory R; Sachs-Barrable K; Goshko CB; Hill JS; Wasan KM
Transplantation; 2009 Jul; 88(1):62-8. PubMed ID: 19584682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
